Skip to main content

Table 1 Baseline characteristics of patients with relapsed/refractory lymphoma initiating salvage chemotherapy in Lilongwe

From: Salvage chemotherapy for adults with relapsed or refractory lymphoma in Malawi

  Total (n = 21) HIV+ (n = 13) HIV- (n = 8)
Age, years 40 (16–78) 49 (16–63) 22 (18–78)
Male, n (%) 12 (57%) 8 (62%) 4 (50%)
Histologic diagnosis, n (%)
 Diffuse large B-cell lymphoma 6 (29%) 3 (23%) 3 (38%)
 Burkitt lymphoma 2 (10%) 2 (25%)
 Plasmablastic lymphoma 2 (10%) 2 (15%)
 Aggressive B-cell NHL NOS 8 (38%) 8 (62%)
 Classical Hodgkin lymphoma 3 (14%) 3 (38%)
Refractory, n (%) 3 (14%) 1 (8%) 2 (25%)
Relapsed, n (%) 18 (86%) 12 (92%) 6 (75%)
Time to relapse from first-line chemotherapy completion, months 3.0 (0.7–19.4) 3.0 (0.7–19.4) 3.6 (0.8–8.1)
Localized disease, n (%) 12 (57%) 10 (77%) 2 (25%)
Largest lymph node mass, cm 6.5 (3–22) 16 (5–35) 11 (2–18)
Performance status ≤2, n (%) 18 (86%) 12 (92%) 6 (75%)
White blood cells, 103/μL 4.6 (2.7–18.6) 4.4 (3.3–8.9) 4.9 (2.7–18.6)
Absolute neutrophil count, 103/μL 2.9 (0.9–14.3) 2.4 (0.9–6.3) 3.0 (1.3–14.3)
Hemoglobin, g/dL 11.2 (6.0–14.7) 12.2 (9.2–14.7) 10.3 (6.0–14.0)
Platelets, 103/μL 332 (56–767) 312 (204–655) 353 (56–767)
Serum creatinine, mg/dL 0.7 (0.3–2.9) 0.8 (0.4–2.9) 0.6 (0.3–1.0)
eGFR <60 mL/min/1.73m2, n (%) 1 (5%) 1 (13%)
CD4 count if HIV+, cells/μL 139 (12–529)
HIV RNA <400 copies/mL if HIV+, n (%) 11 (85%)
  1. Values indicate median (range) unless otherwise specified
  2. NHL non-Hodgkin lymphoma, NOS not otherwise specified, eGFR estimated glomerular filtration rate